Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis.

@article{Gottlieb2000EffectsOA,
  title={Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis.},
  author={A. Gottlieb and J. Krueger and R. Bright and M. Ling and M. Lebwohl and S. Kang and S. Feldman and M. Spellman and K. Wittkowski and H. Ochs and P. Jardieu and R. Bauer and M. White and R. Dedrick and M. Garovoy},
  journal={Journal of the American Academy of Dermatology},
  year={2000},
  volume={42 3},
  pages={
          428-35
        }
}
BACKGROUND CD11a/CD18 comprise subunits of leukocyte function associated antigen (LFA-1), a T-cell surface molecule important in T-cell activation, T-cell emigration into skin, and cytotoxic T-cell function. OBJECTIVE We explored the immunobiologic and clinical effects of treating moderate to severe psoriasis vulgaris with a single dose of humanized monoclonal antibody against CD11a (hu1124). METHODS This was an open label study with a single dose of hu1124 at doses of 0.03 to 10 mg/kg… Expand
Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody.
TLDR
At doses of 0.3 mg/kg or more per week, intravenous efalizumab produced significant clinical and histologic improvement in psoriasis, which correlated with sustained serum efalIZumab levels and T-cell CD11a saturation and down-modulation. Expand
Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody.
TLDR
A single dose of IDEC-114 appears to be safe and well tolerated and has promising clinical activity in psoriasis. Expand
Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab
TLDR
Clinical trials demonstrate that efalizumab, given subcutaneously once-weekly, provides clinical benefit, including improved quality of life, in patients with moderate-to-severe plaque psoriasis, and data indicate that the drug can be safely administered for extended periods of time. Expand
An Overview of the Pharmacokinetics and Pharmacodynamics of Efalizumab: A Monoclonal Antibody Approved for Use in Psoriasis
TLDR
During long‐term administration of efalizumab, serum levels were generally stable and pharmacodynamic markers remained maximally affected, and higher doses did not alter the safety profile. Expand
A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.
TLDR
Efalizumab therapy resulted in significant improvements in plaque psoriasis in subjects with moderate-to-severe disease, and extending treatment from 12 to 24 weeks resulted in both maintenance and improvement of responses. Expand
The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma.
TLDR
Blocking of LFA-1/intercellular adhesion module interactions by efalizumab inhibits the development of allergen-induced cellular inflammatory responses measured in induced sputum and might attenuate the late asthmatic response. Expand
FR255734, a humanized, Fc-Silent, Anti-CD28 antibody, improves psoriasis in the SCID mouse-psoriasis xenograft model.
TLDR
In psoriasis, CD28/B7 costimulatory molecules are well characterized and in vitro studies have shown that FR255734 effectively blocked T-cell proliferation and proinflammatory cytokine production, and these observations warrant studies to evaluate the efficacy of FR25 5734 in human autoimmune diseases. Expand
TISSUE DISTRIBUTION AND RECEPTOR-MEDIATED CLEARANCE OF ANTI-CD11A ANTIBODY IN MICE
TLDR
Assessment of the tissue distribution, cellular internalization, and subcellular localization of a rat anti-mouse CD11a monoclonal antibody in various tissues in mice suggest that one clearance mechanism for anti-CD11a antibody in vivo is via receptor-mediated internalization and lysosomal degradation by CD 11a-expressing cells and tissues. Expand
Effect of therapeutic integrin (CD11a) blockade with efalizumab on immune responses to model antigens in humans: results of a randomized, single blind study.
TLDR
The results expand knowledge of how immune responses are modulated in humans by CD11a blockade and have implications for vaccinations of patients treated with this agent. Expand
Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin.
TLDR
It is concluded that efalizumab most likely blocks cutaneous entry of memory CD8(+) T cells, a highly disease-relevant cell population in psoriasis patients. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 15 REFERENCES
CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris.
TLDR
A potential therapeutic use for this novel immunomodulatory approach in an array of T cell-mediated diseases is suggested. Expand
IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach.
TLDR
Investigations demonstrate the major importance of IL-10 in psoriasis and show thatIL-10 administration represents a new therapeutic approach, and is the first report on IL- 10 therapy for cutaneous disorders. Expand
Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis
TLDR
The reversal of several molecular markers of epidermal dysfunction was associated with a marked reduction in intraepidermal CD3+ and CD8+ T cells, suggesting a primary immunological basis for this widespread disorder. Expand
Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells
TLDR
The hypothesis that epidermal alterations in psoriasis can be normalized by a depletion of activated intraepidermal T cells is supported by a study of the effects of UVB on keratinocytes and leukocytes in psoriatic tissue and in culture. Expand
Expression of HLA-DR molecules by keratinocytes, and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques
TLDR
HLA-DR expression by keratinocytes correlated with disease activity and was reversible with successful medical therapy, providing further support for the hypothesis that immunological mechanisms play an important role in the pathogenesis of psoriasis. Expand
Severe psoriasis--oral therapy with a new retinoid.
TLDR
Ro 10--9359 proved to be an extremely potent antipsoriatic drug and a more than 90% reduction of psoriatic lesions could be seen in 10 patients out of 20 after 4-8 weeks of treatment. Expand
Regulatory properties of LFA-1 α and β chains in human T-lymphocyte activation
TLDR
Data indicate that binding of ligand to LFA-1 results in the transduction of regulatory signals across the plasma membrane, rather like other molecules (CD2, CD4, CDS) with signal-modifying properties involved in the adhesion of T cells to target/stimulator cells. Expand
The role of adhesion molecules in the regulation of antibody responses.
TLDR
Patients and guinea pigs deficient in early complement components, patients deficient in CD11/CD18, and patients lacking functional gp39 on activated T cells responded to repeated phage immunizations with depressed antibody titers, lack of or inadequate amplification, and failure to switch from IgM to IgG, suggesting that defective T-cell-B-cell interaction is the cause of the antibody deficiency observed in patients. Expand
Role of the CD28 receptor in T-cell activation.
TLDR
CD28 serves as the surface component of a novel signal transduction pathway that modulates T-cell lymphokine production and increases the resistance of T- cell responses to various immunosuppressive agents. Expand
Adhesion receptors of the immune system
TLDR
Three families of cell-surface molecules regulate the migration of lymphocytes and the interactions of activated cells during immune responses. Expand
...
1
2
...